172 related articles for article (PubMed ID: 28868573)
1. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies.
Shi M; Sun J; Zhou J; Yu H; Yu S; Xia G; Wang L; Teng Y; Liu G; Yu C; Feng J; Shen Y
Invest New Drugs; 2018 Apr; 36(2):269-277. PubMed ID: 28868573
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
Kim TY; Kim DW; Chung JY; Shin SG; Kim SC; Heo DS; Kim NK; Bang YJ
Clin Cancer Res; 2004 Jun; 10(11):3708-16. PubMed ID: 15173077
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of polymeric micelle‑formulated paclitaxel in adult Chinese patients with advanced solid tumors.
Lv F; Cao J; Zhang J; Qian J; Peng W; Sun S; Li W; Zhang W; Guo W; Li J
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1173-9. PubMed ID: 24658629
[TBL] [Abstract][Full Text] [Related]
4. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation.
Hamaguchi T; Kato K; Yasui H; Morizane C; Ikeda M; Ueno H; Muro K; Yamada Y; Okusaka T; Shirao K; Shimada Y; Nakahama H; Matsumura Y
Br J Cancer; 2007 Jul; 97(2):170-6. PubMed ID: 17595665
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
[TBL] [Abstract][Full Text] [Related]
6. Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study.
Borgå O; Henriksson R; Bjermo H; Lilienberg E; Heldring N; Loman N
Adv Ther; 2019 May; 36(5):1150-1163. PubMed ID: 30879251
[TBL] [Abstract][Full Text] [Related]
7. An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).
Lee SW; Kim YM; Kim YT; Kang SB
J Gynecol Oncol; 2017 May; 28(3):e26. PubMed ID: 28028994
[TBL] [Abstract][Full Text] [Related]
8. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
Burris HA; Infante JR; Anthony Greco F; Thompson DS; Barton JH; Bendell JC; Nambu Y; Watanabe N; Jones SF
Cancer Chemother Pharmacol; 2016 May; 77(5):1079-86. PubMed ID: 27061418
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors.
Yamada K; Yamamoto N; Yamada Y; Mukohara T; Minami H; Tamura T
Jpn J Clin Oncol; 2010 May; 40(5):404-11. PubMed ID: 20133335
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.
Kim SC; Kim DW; Shim YH; Bang JS; Oh HS; Wan Kim S; Seo MH
J Control Release; 2001 May; 72(1-3):191-202. PubMed ID: 11389998
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
Cristea MC; Frankel P; Synold T; Rivkin S; Lim D; Chung V; Chao J; Wakabayashi M; Paz B; Han E; Lin P; Leong L; Hakim A; Carroll M; Prakash N; Dellinger T; Park M; Morgan RJ
Cancer Chemother Pharmacol; 2019 Mar; 83(3):589-598. PubMed ID: 30623229
[TBL] [Abstract][Full Text] [Related]
14. [A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor].
Teng XY; Guan ZZ; Yao ZW; Liu DG; Zhou NN; Luo HY; Hawkins M; Soon-Shiong P
Ai Zheng; 2004 Nov; 23(11 Suppl):1431-6. PubMed ID: 15566651
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.
Hong YS; Kim KP; Lim HS; Bae KS; Ryu MH; Lee JL; Chang HM; Kang YK; Kim H; Kim TW
Invest New Drugs; 2013 Jun; 31(3):616-22. PubMed ID: 22695940
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
Plummer R; Ghielmini M; Calvert P; Voi M; Renard J; Gallant G; Gupta E; Calvert H; Sessa C
Clin Cancer Res; 2002 Sep; 8(9):2788-97. PubMed ID: 12231518
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors.
Mukai H; Kato K; Esaki T; Ohsumi S; Hozomi Y; Matsubara N; Hamaguchi T; Matsumura Y; Goda R; Hirai T; Nambu Y
Invest New Drugs; 2016 Dec; 34(6):750-759. PubMed ID: 27595901
[TBL] [Abstract][Full Text] [Related]
18. An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021).
Lee SW; Kim YM; Cho CH; Kim YT; Kim SM; Hur SY; Kim JH; Kim BG; Kim SC; Ryu HS; Kang SB
Cancer Res Treat; 2018 Jan; 50(1):195-203. PubMed ID: 28324920
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Lee JL; Ahn JH; Park SH; Lim HY; Kwon JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Invest New Drugs; 2012 Oct; 30(5):1984-90. PubMed ID: 22012004
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
Nyman DW; Campbell KJ; Hersh E; Long K; Richardson K; Trieu V; Desai N; Hawkins MJ; Von Hoff DD
J Clin Oncol; 2005 Nov; 23(31):7785-93. PubMed ID: 16258082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
